{
    "root": "2f2fccc5-9cbf-27d6-e063-6294a90a55f9",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Potassium Phosphates",
    "value": "20250228",
    "ingredients": [
        {
            "name": "WATER",
            "code": "059QF0KO0R"
        },
        {
            "name": "NITROGEN",
            "code": "N762921K75"
        },
        {
            "name": "MONOBASIC POTASSIUM PHOSPHATE",
            "code": "4J9FJ0HL51"
        },
        {
            "name": "DIBASIC POTASSIUM PHOSPHATE",
            "code": "CI71S98N1Z"
        }
    ],
    "indications": "potassium phosphates injection indicated source phosphorus : intravenous fluids correct hypophosphatemia adults pediatric patients oral enteral replacement possible , insufficient contraindicated . parenteral nutrition adults pediatric patients oral enteral nutrition possible , insufficient contraindicated .",
    "contraindications": "administer intravenously dilution admixing larger volume fluid . ( 2.1 ) potassium phosphates injection provides phosphorus 3 mmol/ml ( potassium 4.4 meq/ml ) . ( 2.2 , 2.4 ) monitor serum phosphorus , potassium , calcium , magnesium concentrations . ( 2.2 , 2.4 ) full prescribing information instructions preparation . ( 2.1 , 2.3 ) recommended correction hypophosphatemia intravenous fluids potassium phosphates injection patient serum potassium concentration less 4 meq/dl ; otherwise , alternative source phosphorus . ( 2.1 ) dependent upon individual needs patient , contribution phosphorus potassium sources . ( 2.2 ) full prescribing information recommendations initial single dosing , repeated dosing , concentration infusion rate . ( 2.1 , 2.2 ) recommended parenteral nutrition individualize based upon patient ’ condition , nutritional requirements , contribution oral enteral phosphorus potassium intake . ( 2.4 ) full prescribing information recommendations daily maximum . ( 2.4 )",
    "warningsAndPrecautions": "potassium phosphates injection , usp clear colorless solution free visible particulates supplied phosphorus 3 mmol/ml potassium 4.4 meq/ml shown : unit sale strength ndc 69097-078-97 carton containing 25 units phosphorus 15 mmol/5 ml potassium 22 meq/5 ml ndc 69097-078-67 5 ml single dose , plastic vial ndc 69097-077-97 carton containing 25 units phosphorus 45 mmol/15 ml potassium 66 meq/15 ml ndc 69097-077-67 15 ml single dose , plastic vial ndc 69097-055-97 carton containing 25 units phosphorus 150 mmol/50 ml potassium 220 meq/50 ml ndc 69097-055-67 50 ml fill pharmacy bulk package , plastic vial . store 20° 25°c ( 68° 77°f ) [ usp controlled room temperature ] . pharmacy bulk package vial : discard within 4 hours initial entry [ ( 2.3 ) ] . storage admixed solution 2.1 , 2.3 .",
    "adverseReactions": "potassium phosphates injection contraindicated patients : hyperkalemia [ warning ( 5.3 ) ] severe renal impairment ( egfr less 30 ml/min/1.73m2 ) end stage renal disease [ warning ( 5.3 ) ] hyperphosphatemia [ warning ( 5.4 ) ] hypercalcemia significant hypocalcemia [ warning ( 5.4 ) ]",
    "indications_original": "Potassium phosphates injection is indicated as a source of phosphorus:\n                  \n                     in intravenous fluids to correct hypophosphatemia in adults and pediatric patients when oral or enteral replacement is not possible, insufficient or contraindicated.\n                     for parenteral nutrition in adults and pediatric patients when oral or enteral nutrition is not possible, insufficient or contraindicated.",
    "contraindications_original": "Administer intravenously only after dilution or admixing in a larger volume of fluid. ( 2.1 ) Potassium phosphates injection provides phosphorus 3 mmol/mL (potassium 4.4 mEq/mL). ( 2.2 , 2.4 ) Monitor serum phosphorus, potassium, calcium, and magnesium concentrations. ( 2.2 , 2.4 ) See full prescribing information for instructions on preparation and administration. ( 2.1 , 2.3 ) Recommended Dosage for Correction of Hypophosphatemia in Intravenous Fluids Potassium phosphates injection is only for administration to a patient with a serum potassium concentration less than 4 mEq/dL; otherwise, use an alternative source of phosphorus. ( 2.1 ) The dosage is dependent upon the individual needs of the patient, and the contribution of phosphorus and potassium from other sources. ( 2.2 ) See full prescribing information for recommendations on initial or single dosing, repeated dosing, concentration and infusion rate. ( 2.1 , 2.2 ) Recommended Dosage for Administration in Parenteral Nutrition Individualize the dosage based upon the patient’s clinical condition, nutritional requirements, and the contribution of oral or enteral phosphorus and potassium intake. ( 2.4 ) See full prescribing information for recommendations for daily and maximum dosage. ( 2.4 )",
    "warningsAndPrecautions_original": "Potassium phosphates injection, USP is a clear and colorless solution free from visible particulates supplied as phosphorus 3 mmol/mL and potassium 4.4 mEq/mL as shown:\n                   \n                  \n                     \n                     \n                     \n                     \n                        \n                           \n                              Unit of Sale\n                           \n                           \n                              Strength\n                           \n                           \n                              Each\n                           \n                        \n                     \n                     \n                        \n                           \n                              NDC 69097-078-97\n                              Carton containing 25 units\n                           \n                           \n                              Phosphorus 15 mmol/5 mL and Potassium 22 mEq/5 mL\n                           \n                           \n                              NDC 69097-078-67\n                              5 mL single dose, plastic vial\n                           \n                        \n                        \n                           \n                              NDC 69097-077-97\n                              Carton containing 25 units\n                           \n                           \n                              Phosphorus 45 mmol/15 mL and Potassium 66 mEq/15 mL\n                           \n                           \n                              NDC 69097-077-67\n                              15 mL single dose, plastic vial\n                           \n                        \n                        \n                           \n                              NDC 69097-055-97\n                              Carton containing 25 units\n                           \n                           \n                              Phosphorus 150 mmol/50 mL and Potassium 220 mEq/50 mL\n                           \n                           \n                              NDC 69097-055-67\n                              50 mL fill Pharmacy Bulk Package, plastic vial.\n                           \n                        \n                     \n                  \n                   \n                  Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. \n                  Pharmacy Bulk Package vial: Discard within 4 hours of initial entry\n \n  [see Dosage and Administration (\n                     \n                        2.3\n                     \n                     )].\n\n \n                  For storage of admixed solution\n \n  see Dosage and Administration\n                     \n                        2.1\n                     \n                     ,\n                     \n                        2.3\n                     \n                     .",
    "adverseReactions_original": "Potassium phosphates injection is contraindicated in patients with:\n                  \n                     hyperkalemia\n  \n   [see Warning and Precautions (\n                        \n                           5.3\n                        \n                        )]\n                     \n                     severe renal impairment (eGFR less than 30 mL/min/1.73m2) or end stage renal disease\n  \n   [see Warning and Precautions (\n                        \n                           \n                              5.3\n                           \n                        \n                        )]\n                     \n                     hyperphosphatemia\n  \n   [see Warning and Precautions (\n                        \n                           5.4\n                        \n                        )]\n                     \n                     hypercalcemia or significant hypocalcemia\n  \n   [see Warning and Precautions (\n                        \n                           5.4\n                        \n                        )]"
}